HC Wainwright Analysts Cut Earnings Estimates for Korro Bio

Korro Bio, Inc. (NASDAQ:KRRO) – Research analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Korro Bio in a research report issued on Thursday, March 20th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($2.54) for the quarter, down from their prior estimate of ($2.45). HC Wainwright has a “Buy” rating and a $115.00 price objective on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q2 2025 earnings at ($2.67) EPS, Q3 2025 earnings at ($2.82) EPS, Q4 2025 earnings at ($2.97) EPS and FY2025 earnings at ($11.00) EPS.

A number of other equities research analysts have also issued reports on the company. Oppenheimer assumed coverage on Korro Bio in a research report on Friday, January 10th. They issued an “outperform” rating and a $155.00 price target for the company. Royal Bank of Canada dropped their target price on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a report on Wednesday, March 19th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Korro Bio has an average rating of “Buy” and an average price target of $142.57.

Korro Bio Trading Up 1.1 %

KRRO stock opened at $24.03 on Monday. The firm has a 50-day moving average of $29.60 and a two-hundred day moving average of $41.23. Korro Bio has a 12 month low of $18.50 and a 12 month high of $98.00. The company has a market cap of $225.62 million, a price-to-earnings ratio of -2.56 and a beta of 2.13.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share for the quarter, topping the consensus estimate of ($2.33) by $0.07. The business had revenue of $2.27 million during the quarter.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Deep Track Capital LP raised its position in Korro Bio by 2.9% in the fourth quarter. Deep Track Capital LP now owns 874,614 shares of the company’s stock valued at $33,297,000 after purchasing an additional 24,614 shares during the period. Alliancebernstein L.P. acquired a new stake in shares of Korro Bio during the 4th quarter worth about $26,870,000. Driehaus Capital Management LLC raised its holdings in Korro Bio by 220.3% in the 4th quarter. Driehaus Capital Management LLC now owns 494,905 shares of the company’s stock valued at $18,841,000 after buying an additional 340,410 shares during the period. Point72 Asset Management L.P. lifted its position in Korro Bio by 11.0% in the fourth quarter. Point72 Asset Management L.P. now owns 493,997 shares of the company’s stock valued at $18,806,000 after buying an additional 49,147 shares during the last quarter. Finally, Tri Locum Partners LP boosted its stake in Korro Bio by 125.3% during the fourth quarter. Tri Locum Partners LP now owns 144,216 shares of the company’s stock worth $5,490,000 after buying an additional 80,202 shares during the period. 13.18% of the stock is currently owned by institutional investors and hedge funds.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).